LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Начало・Списък с акции・Krystal Biotech Inc

Krystal Biotech Inc

Затворен

СекторЗдравеопазване

302.7 1.14

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

298

Максимум

303.55

Ключови измерители
By Trading Economics
Приходи	4.5M 56M
Продажби	9.3M 116M
P/E Средно за сектора	40.057 49.701
EPS	1.83
Марж на печалбата	48.069
Служители	295
EBITDA	16M 55M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+7.53% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	816M 8.8B
Предишно отваряне	301.56
Предишно затваряне	302.7

Настроения в новините

By Acuity

38%

62%

105 / 344 Класиране в Healthcare

Krystal Biotech Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.05.2026 г., 16:52 ч. UTC

Значими събития в новините

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26.05.2026 г., 23:57 ч. UTC

Печалби

Sociedad Quimica 1Q Rev $1.76B >SQM

26.05.2026 г., 23:57 ч. UTC

Печалби

Sociedad Quimica 1Q EPS $1.28 >SQM

26.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26.05.2026 г., 21:54 ч. UTC

Печалби

Webco Industries 3Q EPS $11.61 >WEBC

26.05.2026 г., 21:54 ч. UTC

Печалби

Webco Industries 3Q Sales $179.6M >WEBC

26.05.2026 г., 21:48 ч. UTC

Пазарно говорене

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26.05.2026 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

26.05.2026 г., 20:58 ч. UTC

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

26.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26.05.2026 г., 19:17 ч. UTC

Пазарно говорене

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26.05.2026 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26.05.2026 г., 18:03 ч. UTC

Пазарно говорене

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26.05.2026 г., 17:42 ч. UTC

Пазарно говорене

Grains Await Fresh Trading Catalyst -- Market Talk

26.05.2026 г., 17:33 ч. UTC

Пазарно говорене

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Canada Faces a Labor Market Squeeze -- Market Talk

26.05.2026 г., 16:52 ч. UTC

Пазарно говорене

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26.05.2026 г., 16:43 ч. UTC

Пазарно говорене

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26.05.2026 г., 16:24 ч. UTC

Пазарно говорене

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26.05.2026 г., 16:21 ч. UTC

Пазарно говорене

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

26.05.2026 г., 16:16 ч. UTC

Пазарно говорене

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26.05.2026 г., 16:01 ч. UTC

Пазарно говорене

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26.05.2026 г., 15:21 ч. UTC

Пазарно говорене

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Krystal Biotech Inc Прогноза

Ценова цел

By TipRanks

7.53% нагоре

12-месечна прогноза

Среден 322 USD 7.53%

Висок 378 USD

Нисък 284 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Krystal Biotech Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Krystal Biotech Inc през последните 3 месеца.

Настроение

By Acuity

105 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.